Efficacy and safety of bedaquiline in treatment regimens in patients TB/HV co-infection in the Udmurt Republic
https://doi.org/10.58838/2075-1230-2023-101-2-80-86
Abstract
The objective: to evaluate the efficacy and safety of bedaquiline in new chemotherapy regimens in HIV-positive tuberculosis patients.
Subjects and Methods. Treatment results of 60 patients with TB/HIV co-infection using treatment regimens containing bedaquiline were analyzed.
Results. Patients with TB/HIV co-infection demonstrated poor adherence to treatment, so 46/60 (76.6%) patients did not complete the intensive phase of chemotherapy. The use of bedaquiline did not cause a critical prolongation of the QT according to ECG results, manifestations of arrhythmia, and it was well combined with ART. Sputum conversion (by culture) was registered in the following cases: by the end of the 2nd month of chemotherapy in 36/60 (60.0%) patients, by the end of the 6th month of chemotherapy – in 11/14 (78.6%) patients.
About the Authors
O. E. Russkikh
Izhevsk State Medical Academy, Russian Ministry of Health
Russian Federation
Russian Federation
Oleg E. Russkikh - Doctor of Medical Sciences, Associate Professor, Head of Phthisiology Department
0/1, Slavyanskoye Highway, Izhevsk, the Udmurt Republic, 426039
Phone: +7 (912) 872-71-06
E. V. Savintseva
Izhevsk State Medical Academy, Russian Ministry of Health
Russian Federation
Russian Federation
Elena V. Savintseva - Assistant of Phthisiology Department
0/1, Slavyanskoye Highway, Izhevsk, the Udmurt Republic, 426039
Phone: +7 (950) 167-38-77
D. A. Kudlay
I. M. Sechenov First Moscow State Medical University; Immunology Research Institute by the Russian Federal Medical Biological Agency
Russian Federation
Russian Federation
Dmitry A. Kudlay - Correspondent Member of RAS, Doctor of Medical Sciences, Professor of Pharmacology Department, Pharmacy Institute, I. M. Sechenov First Moscow State Medical University (Sechenov University); Russian Ministry of Health, Leading Researcher of Laboratory of Personalized Medicine and Molecular Immunology no. 71, Immunology Research Institute
8, Bd. 2, Trubetskaya St., Russia Moscow, 119991
24 Kashirskoye Highway, Moscow, 115552
Phone: +7 (985) 761-02-37
Zh. I. Krivosheeva
Belorussian State Medical University
Belarus
Belarus
Zhanna I. Krivosheeva - Candidate of Medical Sciences, Associate Professor, Head of Phthisiopulmonology Department
83 Dzerzhinskogo Ave., Minsk, 220116
Phone: +375-29-7784506
References
1. Balasanyants G. S. Experience of using bedaquiline in the multimodality therapy of tuberculosis patients with concurrent HIV infection. Tuberculosis and Lung Diseases, 2017, vol. 95, no. 9, pp. 49–54. (In Russ.)
2. Borisov S. E., Filipov A. V., Ivanova D. A., Ivanushkina T. N., Litvinova N. V., Garmash Yu. Yu. Efficacy and safety of chemotherapy regimens with bedaquiline in patients with respiratory tuberculosis: immediate and final results. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 5, pp. 28–40. (In Russ.)
3. Vasilyeva I. A., Samoylova A. G., Lovacheva O. V., Chernousova L. N., Bagdasaryan T. R. The effect of different TB drugs and antimicrobial agents on the efficacy of treatment of tuberculosis patients with multiple drug resistance. Tuberculosis and Lung Diseases, 2017, vol. 95, no. 10, pp. 9–16. (In Russ.)
4. Golubchikov P. N., Kruk E. A., Mishustin S. P., Petrenko T. I., Kudlay D. A. Experience of treating extensive drug resistant tuberculosis patients including continuous use of bedaquiline, in Tomsk Region: immediate and postponed results. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 8, pp. 38–45. (In Russ.)
5. Zhukova E. M., Vokhminova L. G., Kudlay D. A. The effect of the current chemotherapy of MDR/XDR tuberculosis on QT interval changes in ECG. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 11, pp. 19–22. (In Russ.)
6. Informatsionnyy byulleten Epidemicheskaya situatsiya po tuberkulezu v Udmurtskoy Respublike v 2021 godu. [Information bulletin on tuberculosis epidemic situation in the Udmurt Republic in 2021]. Izhevsk, BUZ UR RKTB MZ UR Publ., p. 25.
7. Klinicheskie rekomendatsii Tuberkulez u vzroslykh. [Clinical guidelines on tuberculosis in adults]. MZ RF Publ., 2022, Available: https://cr.minzdrav.gov.ru/recomend/16_2 [Accessed: 18.07.2022].
8. Kondakova M. N., Khabirov V. V., Zhemkov V. F., Shpakovskaya L. R., Daynovets A. V., Elkin A. V. Impact of bedaquiline on the efficacy of comprehensive therapy of respiratory tuberculosis. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 6, pp. 39–43. (In Russ.)
9. Nikolenko N. Yu., Kudlay D. A., Doktorova N. P. Pharmacoepidemiology and pharmacoeconomics of multiple and extensive drug resistant tuberculosis. Farmakoekonomika, Sovremennaya Farmakoekonomika i Farmakoehpidemiologiya, 2021, vol. 14, no. 2, pp. 235–248. (In Russ.)
10. Pirogova N. D., Leshok S. N., Schipunova L. V., Beloborodova N. G. Use of bedaquiline in the chemotherapy regimen for multiple drug resistant tuberculosis in the HIV positive patient. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 10, pp. 53–58. (In Russ.)
11. Russkikh O. E., Stakhanov V. A., Polushkina E. E. Epidemicheskaya situatsiya po tuberkulezu v petitentsiarnom i grazhdanskom sektorakh Udmurtskoy Respubliki. [Tuberculosis epidemiological situation in the civilian and penitentiary sectors of the Udmurt Republic]. Izhevsk, 2007, рр. 68.
12. Skryagina E. M., Gurevich G. L., Solodovnikova V. V., Dyusmikeeva M. I., Setkina S. B., Zhurkin D. M. Experience of treating multiple/extensive drug resistant tuberculosis with new regimens in Belarus Republic. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 8, pp. 5–14. (In Russ.)
13. Tikhonov A. M., Burakova M. V., Vaniev E. V., Romanov V. V., Vasilyeva I. A. Efficiency of chemotherapy with bedaquiline in drug resistant pulmonary tuberculosis patients. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 2, pp. 22–26. (In Russ.)
14. Diacon A. H., Pym A., Grobusch M. P., et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N. Engl. J. Med., 2014, vol. 371, no. 8, pp. 723–732.
15. Jones J., Mudaly V., Voget J., Naledi T., Maartens G., Cohen K. Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases. BMC Infect. Dis., 2019, vol. 19, no. 1, p. 544.
16. O'Donnell M. R., Padayatchi N., Daftary A., Orrell C., Dooley K. E., Rivet Amico K., Friedland G. Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection. Lancet HIV, 2019, vol. 6, no. 3, pp. 201–204.
17. Pandie M., Wiesner L., McIlleron H., et al. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV infected patients with drug-resistant TB. J. Antimicrob. Chemother., 2016, vol. 71, pp. 1037–1040.
18. Pym A., Diacon A., Conradie F. et al. Bedaquiline as part of multi-drag resistant tuberculosis (MDR-TB) therapy regimen: final results of a single-arm, phase II trial (C209). Int. J. Tuberc. Lung Dis., 2013, vol. 17, suppl. 2, p. 236.
19. Schnippel K., Ndjeka N., Maartens G., et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir. Med., 2018, vol. 6, no. 9, pp. 699–706.
20. Treatment Guidelines for Drug-Resistant Tuberculosis. Geneva, World Health Organization, 2016, p. 96.
Review
For citations:
Russkikh O.E., Savintseva E.V., Kudlay D.A., Krivosheeva Zh.I. Efficacy and safety of bedaquiline in treatment regimens in patients TB/HV co-infection in the Udmurt Republic. Tuberculosis and Lung Diseases. 2023;101(2):80-86. (In Russ.) https://doi.org/10.58838/2075-1230-2023-101-2-80-86
Views:
521
Email this article 